For example, for the FDA approved drug ado-trastuzumab emtansine, the phase III clinical trial suggested that patients with increased breast tumor HER2 expression levels demonstrated improved progression-free survival and overall survival, median and low expression of HER2 resulted in median and lower overall survival, respectively [75]. This evidence concerns the gene ERBB2 and breast neoplasm.